[{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ensatinib","moa":"ALK","graph1":"Oncology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Betta Pharmaceuticals \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Fudan University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Betta Pharmaceuticals \/ Fudan University","highestDevelopmentStatusID":"10","companyTruncated":"Betta Pharmaceuticals \/ Fudan University"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Xcovery","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Betta Pharmaceuticals \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Betta Pharmaceuticals \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Betta Pharmaceuticals \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ EyePoint Pharmaceuticals"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"14-C D-0316","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Befotertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"D-0316","moa":"EGFR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BPI-361175","moa":"EGFR C797S\/EGFR T790M\/EGFR exon 19 deletion","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"C4 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"C4 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0.39000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.39000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BPI-15086","moa":"EGFR T790M","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Betta Pharmaceuticals \/ Quintiles Inc","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Quintiles Inc"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Betta Pharmaceuticals \/ Tigermed","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Tigermed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Tigermed","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Tigermed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"The First Affiliated Hospital of Xiamen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ The First Affiliated Hospital of Xiamen University","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ The First Affiliated Hospital of Xiamen University"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase IV","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BPI-9016M","moa":"Hepatocyte growth factor receptor | Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"BPI-9016M","moa":"Hepatocyte growth factor receptor | Tyrosine-protein kinase receptor UFO","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BPI-452080","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BPI-421286","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MRX2843","moa":"MERTK\/FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BPI-371153","moa":"PDL1","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BPI-21668","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Agenus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Balstilimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Betta Pharmaceuticals \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Balstilimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Betta Pharmaceuticals \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Balstilimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Infusion","sponsorNew":"Betta Pharmaceuticals \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Clofarabine","moa":"Ribonucleoside-diphosphate reductase RR1 | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BPI-442096","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BPI-460372","moa":"TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BPI-28592","moa":"TrkA","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BPB-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BPI-16350","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BPI-16350","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BPI-16350","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BPI-3016","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Beijing Mabworks Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase III","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Betta Pharmaceuticals \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Befotertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Betta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Li Peng","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Li Peng","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Li Peng"}]
Find Clinical Drug Pipeline Developments & Deals by Betta Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
